Acta Pharmacologica Sinica

Contents

Monthly 2024 January; 45 (1)

Acta Pharmacologica Sinica

Contents

Monthly 2024 January; 45 (1)

Cover

DZ2002, a reversible inhibitor of type III *S*-adenosyl-*L*-homocysteine hydrolase, attenuates TNF-α-induced NF-κB signaling by suppressing the degradation and phosphorylation of IκB, along with NF-κB p65 phosphorylation and nuclear translocation. Additionally, DZ2002 inhibits the activation of molecules in the STAT3-PI3K-Akt pathway, suppressing the secretion of inflammatory cytokines and pro-angiogenic factors. These findings strongly support DZ2002's promising therapeutic potential for dry eye disease. See the article in pages 166–179.

EXECUTIVE EDITOR FOR THIS ISSUE ZHU, Qian-rong (Shanghai)

ACTA PHARMACOLOGICA SINICA (Monthly)
2024 January; Volume 45 Number 1
(Founded in September, 1980)

Sponsored by
Chinese Pharmacological Society
Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Supervised by
China Association for Science and Technology
Editor-in-chief
DING, Jian
Edited by
Editorial Board of Acta Pharmacologica Sinica
294 Tai-yuan Road, Shanghai 200031, China
Http://www.chinaphar.com
E-mail aps@simm.ac.cn
Phn 86-21-5492-2821, 5492-2822; Fax 86-21-5492-2823

Published jointly by
Editorial Office of Acta Pharmacologica Sinica
Springer Nature
Publication date
5th every month
Printed by
Shanghai Shengtong Times Printing Co Ltd
568 Guang-ye Road, Shanghai 201506, China

《中国药理学报》编辑部出版
国内统一连续出版物号
CN 31-1347/R

国内外公开发行
国内邮发代号 4-295
国内每期 200.00 元